SPDR S&P Pharmaceuticals (XPH) 123.68 $XPH
Pharma ETFs In Focus On Valeant-Salix Deal
Zacks Funds - Seeking Alpha - Wed Feb 25, 6:44AM CST
After a blockbuster 2014, the healthcare space continues its mergers and acquisitions this year as well. The latest catalyst in the space is the Canadian drug maker Valeant Pharmaceuticals International (NYSE: VRX ), which is set to acquire leading...
PPH: 69.20 (-0.28), VRX: 197.48 (-3.77), PJP: 75.81 (-0.55), SLXP: 157.20 (+0.25), XPH: 123.68 (-1.05)
Pharma ETFs in Focus on Valeant-Salix Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Feb 24, 8:00AM CST
The M&A deal has put the pharma ETFs in focus over the coming days.
PPH: 69.20 (-0.28), VRX: 197.48 (-3.77), PJP: 75.81 (-0.55), SLXP: 157.20 (+0.25), XPH: 123.68 (-1.05)
Pharma And Biotech Funds Add Zest To Your Portfolio
John Dowdee - at Seeking Alpha - Fri Feb 13, 7:10AM CST
PBE: 54.82 (-0.72), HQL: 28.10 (-0.22), FBT: 115.23 (-0.93), PJP: 75.81 (-0.55), XBI: 214.63 (-3.26), XPH: 123.68 (-1.05), IBB: 337.47 (-3.33), HQH: 35.19 (-0.24)
Can Pharma ETFs Continue Their Uptrend In 2015?
Zacks Funds - Seeking Alpha - Fri Jan 09, 4:37PM CST
The pharmaceutical sector, which had been witnessing several tax inversion deals over the last few months, is not likely to go down this route given the Sep 2014 notice issued by the U.S. Department of the Treasury. New rules imposed by the Treasury...
IHE: 168.40 (-1.32), PPH: 69.20 (-0.28), PJP: 75.81 (-0.55), XPH: 123.68 (-1.05)
Can Pharma ETFs Continue their Uptrend in 2015? - ETF News And Commentary
Zacks Equity Research - ZACKS - Fri Jan 09, 11:00AM CST
Several factors suggest that Pharma ETFs may continue their strong performance this year as well.
IHE: 168.40 (-1.32), PPH: 69.20 (-0.28), PJP: 75.81 (-0.55), XPH: 123.68 (-1.05)
Where Do Cures Reside? The Answer Is In Regenerative Medicine
Life Sciences Report - Seeking Alpha - Fri Jan 09, 7:37AM CST
The practice of medicine is being transformed. The journey has been arduous, but revolutionary stem cell, gene and immunocellular therapies are rapidly moving toward pivotal milestones-and investors in the space should strap in for a rewarding joy...
BBP: 30.13 (-0.29), RXL: 138.47 (-1.10), XBI: 214.63 (-3.26), IHE: 168.40 (-1.32), IHF: 127.24 (+0.23), PPH: 69.20 (-0.28), XHE: 93.16 (-0.49), BBC: 31.07 (-0.57), PTH: 58.61 (-0.63), BBH: 127.98 (-1.22), FHLC: 35.00 (-0.18), IHI: 119.02 (-0.51), CURE: 144.50 (-2.04), FXH: 64.53 (-0.35), VHT: 133.62 (-0.69), RYH: 151.78 (-0.58), PBE: 54.82 (-0.72), IYH: 153.01 (-0.71), FBT: 115.23 (-0.93), XHS: 120.36 (+0.82), XPH: 123.68 (-1.05), XLV: 72.24 (-0.35), SBIO: 29.21 (-0.29), PSCH: 66.18 (+0.09), PJP: 75.81 (-0.55), RXD: 13.33 (+0.09)
Kyle Bass's Assault On Pharma Patents
IP Hawk - at Seeking Alpha - Thu Jan 08, 12:25PM CST
BBP: 30.13 (-0.29), RXL: 138.47 (-1.10), XBI: 214.63 (-3.26), IBB: 337.47 (-3.33), IHE: 168.40 (-1.32), IHF: 127.24 (+0.23), BBC: 31.07 (-0.57), PPH: 69.20 (-0.28), XHE: 93.16 (-0.49), PTH: 58.61 (-0.63), BBH: 127.98 (-1.22), FHLC: 35.00 (-0.18), IHI: 119.02 (-0.51), CURE: 144.50 (-2.04), FXH: 64.53 (-0.35), VHT: 133.62 (-0.69), RYH: 151.78 (-0.58), PBE: 54.82 (-0.72), IYH: 153.01 (-0.71), FBT: 115.23 (-0.93), XHS: 120.36 (+0.82), XPH: 123.68 (-1.05), XLV: 72.24 (-0.35), SBIO: 29.21 (-0.29), PSCH: 66.18 (+0.09), PJP: 75.81 (-0.55), RXD: 13.33 (+0.09)
SPDR S&P Pharmaceuticals ETF announces quarterly distribution of $5.487
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 1:01PM CST
XPH: 123.68 (-1.05)
What Kinds Of ETFs Are Making Capital Gains Distributions This Year?
Morningstar - Seeking Alpha - Fri Dec 05, 3:45AM CST
By Robert Godsborough For investors, one of the most appealing aspects of exchange-traded funds is their clear tax efficiency. To start with, many passive funds inherently are low-turnover vehicles, with a minimal amount of concentrated buying...
BOND: 109.53 (-0.04), XPH: 123.68 (-1.05), AGG: 111.20 (+0.28), FM: 30.61 (-0.18), BND: 83.08 (+0.07), RSCO: 87.18 (+0.30), SDY: 79.27 (-0.15)
OKS, XPO, XPH, WU, MVO, ARAY Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 03, 7:24AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ONEOK PARTNERS, L.P. (NYSE:OKS), XPO Logistics Inc (NYSE:XPO), Spdr S&P Pharmaceuticals Etf (NYSE:XPH), Western Union Co (NYSE:WU), MV Oil Trust (NYSE:MVO), Accuray Inc (NASDAQ:ARAY) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
WU: 19.52 (-0.07), OKE: 44.26 (+0.29), XPH: 123.68 (-1.05), OKS: 41.79 (+1.16), ARAY: 8.98 (+0.27), MVO: 15.39 (-0.05), XPO: 44.15 (+0.22)
Pharma ETFs In Focus On Allergan Takeover Deal
Zacks Funds - at Seeking Alpha - Sat Nov 22, 9:10PM CST
The health care space is witnessing 2014 as another banner year thanks to encouraging industry trends, solid corporate earnings and huge levels of merger and acquisition activities. The sector is clearly leading the broad market rally and this trend...
IHE: 168.40 (-1.32), AGN: 232.74 (+0.34), PPH: 69.20 (-0.28), ACT: 291.36 (+1.58), XPH: 123.68 (-1.05)
Pharma ETFs in Focus on Allergan Takeover Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Nov 18, 12:00PM CST
Pharma ETFs could get further boost from Actavis and Allergan merger deal in the coming days.
IHE: 168.40 (-1.32), AGN: 232.74 (+0.34), VRX: 197.48 (-3.77), PPH: 69.20 (-0.28), ACT: 291.36 (+1.58), XPH: 123.68 (-1.05)
Best ETF Strategies for the Fourth Quarter - ETF News And Commentary
Neena Mishra - Zacks Investment Research - Mon Sep 22, 1:25PM CDT
The stock market may add to its gains in Q4 and these ETFs look well positioned to outperform the broader space.
DXJ: 53.87 (-0.21), MOAT: 30.91 (+0.03), QUAL: 64.85 (-0.10), XPH: 123.68 (-1.05), IEO: 74.49 (-0.78)
The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical
PR Newswire - Mon Aug 25, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Powershares Dynamic Pharmaceuticals ETF (AMEX
JP-Free Report), SPDR S&P Pharmaceuticals ETF (AMEX:XPH-Free Report), iShares U.S. Pharmaceuticals (AMEX:IHE-Free Report) and Market Vectors Pharmaceutical (AMEX PH-Free Report).
XPH: 123.68 (-1.05)
Pharma ETF Investing 101 - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 9:00AM CDT
Rising demand from emerging markets and new products will continue to drive growth in the pharma industry.
IHE: 168.40 (-1.32), PJP: 75.81 (-0.55), XPH: 123.68 (-1.05)
Pharma ETFs In Focus On Valeant-Salix Deal
Zacks Funds - Seeking Alpha - Wed Feb 25, 6:44AM CST
After a blockbuster 2014, the healthcare space continues its mergers and acquisitions this year as well. The latest catalyst in the space is the Canadian drug maker Valeant Pharmaceuticals International (NYSE: VRX ), which is set to acquire leading...
PPH: 69.20 (-0.28), VRX: 197.48 (-3.77), PJP: 75.81 (-0.55), SLXP: 157.20 (+0.25), XPH: 123.68 (-1.05)
Pharma ETFs in Focus on Valeant-Salix Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Feb 24, 8:00AM CST
The M&A deal has put the pharma ETFs in focus over the coming days.
PPH: 69.20 (-0.28), VRX: 197.48 (-3.77), PJP: 75.81 (-0.55), SLXP: 157.20 (+0.25), XPH: 123.68 (-1.05)
Pharma And Biotech Funds Add Zest To Your Portfolio
John Dowdee - at Seeking Alpha - Fri Feb 13, 7:10AM CST
PBE: 54.82 (-0.72), HQL: 28.10 (-0.22), FBT: 115.23 (-0.93), PJP: 75.81 (-0.55), XBI: 214.63 (-3.26), XPH: 123.68 (-1.05), IBB: 337.47 (-3.33), HQH: 35.19 (-0.24)
Can Pharma ETFs Continue Their Uptrend In 2015?
Zacks Funds - Seeking Alpha - Fri Jan 09, 4:37PM CST
The pharmaceutical sector, which had been witnessing several tax inversion deals over the last few months, is not likely to go down this route given the Sep 2014 notice issued by the U.S. Department of the Treasury. New rules imposed by the Treasury...
IHE: 168.40 (-1.32), PPH: 69.20 (-0.28), PJP: 75.81 (-0.55), XPH: 123.68 (-1.05)
Can Pharma ETFs Continue their Uptrend in 2015? - ETF News And Commentary
Zacks Equity Research - ZACKS - Fri Jan 09, 11:00AM CST
Several factors suggest that Pharma ETFs may continue their strong performance this year as well.
IHE: 168.40 (-1.32), PPH: 69.20 (-0.28), PJP: 75.81 (-0.55), XPH: 123.68 (-1.05)
Where Do Cures Reside? The Answer Is In Regenerative Medicine
Life Sciences Report - Seeking Alpha - Fri Jan 09, 7:37AM CST
The practice of medicine is being transformed. The journey has been arduous, but revolutionary stem cell, gene and immunocellular therapies are rapidly moving toward pivotal milestones-and investors in the space should strap in for a rewarding joy...
BBP: 30.13 (-0.29), RXL: 138.47 (-1.10), XBI: 214.63 (-3.26), IHE: 168.40 (-1.32), IHF: 127.24 (+0.23), PPH: 69.20 (-0.28), XHE: 93.16 (-0.49), BBC: 31.07 (-0.57), PTH: 58.61 (-0.63), BBH: 127.98 (-1.22), FHLC: 35.00 (-0.18), IHI: 119.02 (-0.51), CURE: 144.50 (-2.04), FXH: 64.53 (-0.35), VHT: 133.62 (-0.69), RYH: 151.78 (-0.58), PBE: 54.82 (-0.72), IYH: 153.01 (-0.71), FBT: 115.23 (-0.93), XHS: 120.36 (+0.82), XPH: 123.68 (-1.05), XLV: 72.24 (-0.35), SBIO: 29.21 (-0.29), PSCH: 66.18 (+0.09), PJP: 75.81 (-0.55), RXD: 13.33 (+0.09)
Kyle Bass's Assault On Pharma Patents
IP Hawk - at Seeking Alpha - Thu Jan 08, 12:25PM CST
BBP: 30.13 (-0.29), RXL: 138.47 (-1.10), XBI: 214.63 (-3.26), IBB: 337.47 (-3.33), IHE: 168.40 (-1.32), IHF: 127.24 (+0.23), BBC: 31.07 (-0.57), PPH: 69.20 (-0.28), XHE: 93.16 (-0.49), PTH: 58.61 (-0.63), BBH: 127.98 (-1.22), FHLC: 35.00 (-0.18), IHI: 119.02 (-0.51), CURE: 144.50 (-2.04), FXH: 64.53 (-0.35), VHT: 133.62 (-0.69), RYH: 151.78 (-0.58), PBE: 54.82 (-0.72), IYH: 153.01 (-0.71), FBT: 115.23 (-0.93), XHS: 120.36 (+0.82), XPH: 123.68 (-1.05), XLV: 72.24 (-0.35), SBIO: 29.21 (-0.29), PSCH: 66.18 (+0.09), PJP: 75.81 (-0.55), RXD: 13.33 (+0.09)
SPDR S&P Pharmaceuticals ETF announces quarterly distribution of $5.487
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 1:01PM CST
XPH: 123.68 (-1.05)
What Kinds Of ETFs Are Making Capital Gains Distributions This Year?
Morningstar - Seeking Alpha - Fri Dec 05, 3:45AM CST
By Robert Godsborough For investors, one of the most appealing aspects of exchange-traded funds is their clear tax efficiency. To start with, many passive funds inherently are low-turnover vehicles, with a minimal amount of concentrated buying...
BOND: 109.53 (-0.04), XPH: 123.68 (-1.05), AGG: 111.20 (+0.28), FM: 30.61 (-0.18), BND: 83.08 (+0.07), RSCO: 87.18 (+0.30), SDY: 79.27 (-0.15)
OKS, XPO, XPH, WU, MVO, ARAY Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 03, 7:24AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ONEOK PARTNERS, L.P. (NYSE:OKS), XPO Logistics Inc (NYSE:XPO), Spdr S&P Pharmaceuticals Etf (NYSE:XPH), Western Union Co (NYSE:WU), MV Oil Trust (NYSE:MVO), Accuray Inc (NASDAQ:ARAY) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
WU: 19.52 (-0.07), OKE: 44.26 (+0.29), XPH: 123.68 (-1.05), OKS: 41.79 (+1.16), ARAY: 8.98 (+0.27), MVO: 15.39 (-0.05), XPO: 44.15 (+0.22)
Pharma ETFs In Focus On Allergan Takeover Deal
Zacks Funds - at Seeking Alpha - Sat Nov 22, 9:10PM CST
The health care space is witnessing 2014 as another banner year thanks to encouraging industry trends, solid corporate earnings and huge levels of merger and acquisition activities. The sector is clearly leading the broad market rally and this trend...
IHE: 168.40 (-1.32), AGN: 232.74 (+0.34), PPH: 69.20 (-0.28), ACT: 291.36 (+1.58), XPH: 123.68 (-1.05)
Pharma ETFs in Focus on Allergan Takeover Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Nov 18, 12:00PM CST
Pharma ETFs could get further boost from Actavis and Allergan merger deal in the coming days.
IHE: 168.40 (-1.32), AGN: 232.74 (+0.34), VRX: 197.48 (-3.77), PPH: 69.20 (-0.28), ACT: 291.36 (+1.58), XPH: 123.68 (-1.05)
Best ETF Strategies for the Fourth Quarter - ETF News And Commentary
Neena Mishra - Zacks Investment Research - Mon Sep 22, 1:25PM CDT
The stock market may add to its gains in Q4 and these ETFs look well positioned to outperform the broader space.
DXJ: 53.87 (-0.21), MOAT: 30.91 (+0.03), QUAL: 64.85 (-0.10), XPH: 123.68 (-1.05), IEO: 74.49 (-0.78)
The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical
PR Newswire - Mon Aug 25, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Powershares Dynamic Pharmaceuticals ETF (AMEX
JP-Free Report), SPDR S&P Pharmaceuticals ETF (AMEX:XPH-Free Report), iShares U.S. Pharmaceuticals (AMEX:IHE-Free Report) and Market Vectors Pharmaceutical (AMEX PH-Free Report). XPH: 123.68 (-1.05)
Pharma ETF Investing 101 - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 9:00AM CDT
Rising demand from emerging markets and new products will continue to drive growth in the pharma industry.
IHE: 168.40 (-1.32), PJP: 75.81 (-0.55), XPH: 123.68 (-1.05)
